Deep search
Profile Picture
  • All
  • Search
  • Copilot
  • Images
  • Videos
  • Maps
  • News
  • More
    • Shopping
    • Flights
    • Travel
    • Hotels
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
  • Past 7 days
    • Any time
    • Past hour
    • Past 24 hours
    • Past 30 days
  • Most recent
    • Best match

News

The Lancet3d
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Copyright: © 2015 Elsevier Ltd. Published by Elsevier Ltd.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now

Court blocks Trump’s tariffs
Charged w/ rape, trafficking
Sentenced for abusing kids
Kevin Costner sued
Man grabs gun, shoots self
Boil-water advisory issued
Killer heat ahead?
Racist fan behavior probe
Two agents suspended
Violent break-in at CA home
Won’t face death penalty
MO abortion ban reinstated
2nd arrest in torture case
Disappointed w/ Trump's bill
Starship rocket breaks up
Hamas leader killed?
DOGE can access data
To cut federal contracts
Ex-NBA star pleads guilty
Zelenskyy visits Berlin
Iranian man pleads guilty
Manhattanhenge 2025
Judge blocks Trump order
Sumo has a new champion
Judge backs NYC toll plan
Machinists end 3-week strike
Migrant boat capsizes
Jeanine Pirro sworn in
Recalls over 1M vehicles
NYC HS student detained
DOJ sues NC over voter rolls
Rock slide hits Swiss village
OH lawyer pleads not guilty
Lifts most Syria sanctions
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy